Murphy & Mullick Capital Management’s Roivant Sciences ROIV Stock Holding History

Murphy & Mullick Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.54K	Hold	100	–	–	﹤0.01%	587
2026 Q1	$2.77K	Hold	100	–	–	﹤0.01%	587
2025 Q4	$2.17K	Hold	100	–	–	﹤0.01%	606
2025 Q3	$1.96K	Hold	100	–	–	﹤0.01%	598
2025 Q2	$1.13K	Hold	100	–	–	﹤0.01%	620
2025 Q1	$1.01K	Hold	100	–	–	﹤0.01%	614
2024 Q4	$1.18K	Buy	+100	New	+$1.18K	﹤0.01%	592

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Murphy & Mullick Capital Management's ROIV Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its Roivant Sciences (ROIV) position steady in Q2 2026 at 100 shares worth $3.54K. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Murphy & Mullick Capital Management first reported a position in ROIV in Q4 2024 and has held it in 7 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Murphy & Mullick Capital Management held 100 shares of Roivant Sciences worth $3.54K as of Q2 2026.
Murphy & Mullick Capital Management left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #587 holding.
Murphy & Mullick Capital Management first reported a position in Roivant Sciences in Q4 2024 and has held it in 7 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.